Jane Street Group LLC boosted its stake in shares of Opko Health, Inc. (NASDAQ:OPK) by 39.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 491,781 shares of the biotechnology company’s stock after buying an additional 138,835 shares during the period. Jane Street Group LLC owned 0.10% of Opko Health worth $3,934,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Opko Health during the fourth quarter valued at $30,421,000. United Capital Financial Advisers LLC boosted its position in shares of Opko Health by 10.6% in the fourth quarter. United Capital Financial Advisers LLC now owns 62,162 shares of the biotechnology company’s stock valued at $578,000 after buying an additional 5,934 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Opko Health during the fourth quarter valued at $105,000. Envestnet Asset Management Inc. boosted its position in shares of Opko Health by 23.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 15,355 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,927 shares in the last quarter. Finally, Folger Hill Asset Management LP purchased a new position in shares of Opko Health during the fourth quarter valued at $221,000. 23.65% of the stock is owned by institutional investors and hedge funds.
Shares of Opko Health, Inc. (OPK) traded up 1.67% during midday trading on Tuesday, reaching $6.70. The company had a trading volume of 3,875,024 shares. The company’s 50-day moving average is $6.73 and its 200-day moving average is $8.30. Opko Health, Inc. has a 52-week low of $5.99 and a 52-week high of $12.15. The firm’s market cap is $3.75 billion.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The company had revenue of $296.10 million for the quarter, compared to analyst estimates of $313.36 million. During the same period last year, the firm earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 1.8% on a year-over-year basis. Equities research analysts expect that Opko Health, Inc. will post ($0.20) EPS for the current fiscal year.
OPK has been the subject of a number of recent analyst reports. Jefferies Group LLC decreased their price target on Opko Health from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Thursday, March 2nd. Guggenheim initiated coverage on Opko Health in a research report on Tuesday, March 14th. They issued a “buy” rating and a $25.00 price target for the company. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th. Standpoint Research reiterated a “buy” rating and issued a $14.00 price target on shares of Opko Health in a research report on Sunday, March 5th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $19.50 price target on shares of Opko Health in a research report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Buy” and an average target price of $16.58.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 9,200 shares of the firm’s stock in a transaction on Wednesday, March 29th. The stock was purchased at an average cost of $8.14 per share, with a total value of $74,888.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $24,981,261.14. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard A. Lerner bought 10,000 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was acquired at an average cost of $6.31 per share, with a total value of $63,100.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 2,681,200 shares of company stock valued at $18,331,123. Insiders own 40.74% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.